Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating the safety, tolerability and immunogenicity of the investigational RSV vaccine candidate Ad26.RSV.preF in adults 18 to 50 years and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection
• Respiratory Tract Infections

Drugs mentioned

• Ad26.RSV.preF (Ad26.RSV.preF)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Respiratory Syncytial Viruses, Respiratory Tract Infections | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-06-23